AT-527 has demonstrated clinical safety/tolerability and potent antiviral efficacy in patients with HCV infection, as well as a favorable human pharmacokinetic (PK) profile. With potent in vitro activity against human coronaviruses, AT-527 is now being evaluated for the treatment of COVID-19 patients.
Well tolerated in approximately 30 HCV-infected patients treated for 7-days to up to 12-weeks with a QD (once daily) dose of 550mg of AT-527.
High solubility promotes rapid absorption.
Designed for QD or BID (twice daily) oral administration.
Increases the shelf life of therapeutics.